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Abstract
Neisseria gonorrhoeae resistance to cephalosporins, the currently recommended treatment, and treatment failures with ceﬁxime have
been reported worldwide. The purposes of the present study were (i) to examine the susceptibility of N. gonorrhoeae isolates isolated
in Italy from 2006 through 2010 to ceﬁxime (n = 293) taking into account both European Committee on Antimicrobial Susceptibility
Testing (EUCAST) and Clinical And Laboratory Standards Institute (CLSI) criteria for categorization; (ii) to determine the contribution
to decreased/resistant susceptibility of mutations in the penA, mtrR, ponA and porB1b genes in a subsample of isolates; and (iii) to geno-
type the isolates showing decreased susceptibility or resistance to ceﬁxime, by N. gonorrhoeae multi-antigen sequence typing (NG-MAST)
and by pulsed-ﬁeld gel electrophoresis (PFGE) to identify the predominant genotypes. Minimum inhibitory concentrations (MICs) were
determined by the E-test and agar dilution method on 293 isolates and results were interpreted according to both EUCAST 2010 (MIC
R >0.12 mg/L) and CLSI 2008 (MIC R >0.25 mg/L) criteria. All isolates showed full susceptibility to ceftriaxone, whereas those with a
MIC for ceﬁxime ‡0.125 mg/L were on the increase from 2008 through 2010. The same penA gene alterations were found among iso-
lates with MICs close to the EUCAST breakpoint as the resistant ones, and they belong to ST1407. Seven isolates, belonging to various
sequence types, showed a different por allele, though similar to the por 908 allele present in ST1407. PFGE divided strains ST1407 into
two main groups conﬁrming their genetic relationship.
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Introduction
One of the major public health requirements to control gon-
orrhoea is appropriate and effective treatment. Growing
concern over the spread of resistance to antibiotics has
prompted a plethora of recommendations for its control.
The importance of surveillance of antimicrobial resistance
and antibiotic usage and the need to encourage judicious
antibiotic usage have been extensively elucidated, especially
as treatment options for gonorrhoea started to decrease
because of the spread of resistance to sulfonamides, penicil-
lin, tetracyclines and quinolones. Most recently, a warning
was launched concerning the rise of the MIC to the cephalo-
sporins, ceﬁxime and ceftriaxone [1,2]. In Neisseria gonor-
rhoeae, the mosaic structure of the penA gene (encoding
penicillin-binding protein 2), which is composed of fragments
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of the penA genes from commensal Neisseria sp. such as Nei-
sseria cinerea and Neisseria perﬂava, has been signiﬁcantly
associated with decreased susceptibility to cephalosporins,
particularly oral cephalosporins [3–5]. Current treatment
guidelines for gonorrhoea recommend the use of single-dose
injectable or oral cephalosporins. Ceﬁxime is an oral prepa-
ration with a spectrum of activity similar to that of ceftriax-
one. A single oral dose of ceﬁxime 400 mg was shown to
have similar anti-gonococcal efﬁcacy compared with ceftriax-
one for genital infections [6]. There is more extensive use of
injectable ceftriaxone in comparison with oral ceﬁxime [7].
Treatment failures following therapy with ceﬁxime and cef-
tibuten have been reported, but not with the injectable cef-
triaxone [7,8].
The presence of multiple chromosomal changes form the
basis for cephalosporin resistance, the most prominent being
a mosaic penicillin-binding protein 2 found in association with
additional known and unknown mutations in other genes:
mtrR, porB1b, ponA [9–11]. The European Committee on
Antimicrobial Susceptibility Testing (EUCAST), through the
ongoing process of harmonizing European breakpoints, has
proposed a threshold for ceﬁxime and ceftriaxone, recom-
mending that those with MIC >0.12 mg/L are resistant, while
those with MIC £0.12 mg/L should be classed as susceptible
[12]. The most recent approved CLSI breakpoint was
>0.25 mg/L for ceﬁxime-resistant gonococci [13].
The present study set out (i) to establish the susceptibility
to ceﬁxime of N. gonorrhoeae isolates (n = 293) in Italy from
2006 through 2010 taking into account both EUCAST and
CLSI criteria for categorization; (ii) to determine the contri-
bution of mutations in the penA, mtrR, ponA and porB1b genes
in decreased/resistant susceptibility on a subset of isolates;
and (iii) to genotype the strains showing decreased suscep-
tibility or resistance to ceﬁxime, by N. gonorrhoeae multi-
antigen sequence typing (NG-MAST), and by pulsed-ﬁeld gel
electrophoresis (PFGE).
Materials and Methods
Strains and antimicrobial susceptibility determination
Two hundred and ninety-three isolates from male patients
with symptomatic urethritis represented the half of those
received in the study period at the Istituto Superiore di Sanita`
from six different laboratories from the North and from the
Centre of Italy. After growth on Thayer–Martin medium
(Oxoid Ltd, Milan, Italy) with 1% IsoVitalex (Oxoid Ltd) at
37C in a 5% CO2 atmosphere, antimicrobial susceptibility for
ceftriaxone and ceﬁxime was assessed by E-test and by agar
dilution method following standard procedures [1,13].
Clinical breakpoints and epidemiological cut-offs were
those indicated by the EUCAST (Version 1.1 April 2010)
[12] and by clinical breakpoints by the CLSI 2008 [13]. The
EUCAST breakpoint was followed exclusively for ceftriaxone
(susceptible £0.12 mg/L and resistant >0.12 mg/L) because
the lower breakpoint ensured that the levels of decreased
susceptibility were not underestimated. For ceﬁxime the
strains were categorized according to the following deﬁni-
tions: susceptible £0.12 mg/L and resistant >0.12 mg/L for
EUCAST, and susceptible £0.25 mg/L and resistant >0.25mg/L
for CLSI.
The WHO control strains G and K were also tested. MIC
results for the WHO control strain K were within one dou-
bling dilution of the reported levels of 0.25 mg/L for ceﬁxime
and 0.06 mg/L for ceftriaxone [1].
Molecular analyses by gene sequencing of penA, mtrR,
porb1B and ponA genes
For molecular investigation purposes a total of 50 N. gonor-
rhoeae isolates were selected from 2007 through 2010 on
the basis of their ceﬁxime MICs; in particular, 43 had MICs
of 0.12–0.38 mg/L and seven were fully susceptible (MICs
<0.12 mg/L).
The nucleotide sequences were determined as reported
previously [11,14], with minor modiﬁcations. The ampliﬁca-
tion parameters for the penA gene were: 35 cycles of 94C
for 1 min; 54C for 1 min and 72C for 1 min. For all strains
the promoter and coding region of mtrR, ponA and porB1b
were ampliﬁed and sequenced with the primers listed in
Table 1. The ampliﬁcation parameters were: 35 cycles of
95C for 1 min; 54C (mtrR), 46C (poB1b) or 56C (ponA)
for 1 min and 72C for 1 min. Multiple sequence and amino
acid alignments were performed using CROMASPRO version
1.42 and CLUSTALW2 web-site (http://www.ebi.ac.uk/tools/
msa/clustalw2/).
Nucleotide sequence accession number
The N. gonorrhoeae complete penA gene for Penicillin Binding
Protein 2 found in the 1050/09 isolate was deposited in the
TABLE 1. Primers for PCR ampliﬁcation and sequencing of
penA, mtrR, porB1b and ponA genes
Primers Nucleotide sequence (5¢–3¢) Reference
penA-B1 51tgc cgg aat cgg att cct73 This study
penA-A2 597aaa acg cca tta ccc gat ggg617 [11]
penA-PA2 1851aca atc tcg ttg ata ctc g1869 This study
mtrR-1 860aac agg cat tct tat ttc ag878 [14]
mtrR-2 1756tta gaa gaa tgc ttt gtg tc1775 [14]
mtrR-F )210gcc aat caa cag gca ttc tta)191 [11]
porB1b-F )41ccg gcc tgc tta aat ttc tta)22 [11]
porB1b-R 1030tat tag aat ttg tgg cgc ag1049 [11]
ponA-F 1171gag aaa atg ggg gag gac cg1190 [11]
ponA-R 1395ggc tgc cgc att gcc tga ac1376 [11]
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EMBL/GenBank nucleotide sequence database under acces-
sion no. FR852576.
Neisseria gonorrhoeae multi-antigen sequence typing and
PFGE
The NG-MAST and PFGE analyses were performed exclu-
sively on isolates fully characterized by DNA sequencing of
penA, mtrR, porB1b, ponA genes. Alleles at por and tbpB and
sequence types were assigned at the NG-MAST website
(http://www.ng-mast.net) following the interpretative proce-
dures previously described [15]. The two methods were per-
formed on the same culture material.
PFGE DNA preparation followed standard protocols
[16,17]. Digestion with 30 U SpeI restriction enzyme (New
England Biolabs, Ipswich, MA, USA) was performed for 18 h
at 37C. NheI was used to conﬁrm the results obtained with
SpeI enzyme. The gel was stained with 2 mg/mL ethidium
bromide, photographed under UV lights and digitized with a
Gel Doc 2000 system apparatus (Bio-Rad, Hercules, CA,
USA). The PFGE banding patterns were analysed with the
DIVERSITY DATABASE FINGERPRINTING SOFTWARE (version 2; Bio-
Rad). Clustering analysis was performed using Dice coefﬁ-
cient and the unweighted pair-group method (UPGMA) with
a 1.0% tolerance limit and 1.0% optimization using BIONUMERICS
software version 3.5 (Applied Maths, Sint-Martens-Latem,
Belgium). The homology tree obtained was analysed with the
DNAMAN software (version 5.2.10).
Statistical analysis
Chi-squared test and U Mann–Whitney tests were used for
statistical analyses. Signiﬁcance was set at p <0.05.
Results
All the 293 examined strains were fully susceptible to ceftri-
axone with a MIC range of 0.002–0.094 mg/L. Resistance to
ceﬁxime was identiﬁed for 12% of gonococci, according to
the EUCAST breakpoint, and 1% according to the CLSI
(Fig. 1a). Isolates with a MIC for ceﬁxime ‡0.125 mg/L were
on the increase from 2008 through 2010 (Fig. 1b). Two iso-
lates showed high MICs to ceﬁxime of 0.38 mg/L. The DNA
sequencing of the target genes showed the same mutations
found from isolates with a MIC ‡0.12 mg/L. The genotypic
characteristics of analysed isolates are shown in Table 2. The
complete nucleotide sequences of penA from ceﬁxime-sus-
ceptible and ceﬁxime-resistant strains were determined.
They were compared with N. gonorrhoeae strain LM306
(GenBank accession number M32091) and with NG-3 (Gen-
Bank accession number AB071984). Five amino acid
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FIG. 1. Distribution of ceﬁxime MICs among
Italian gonococci from 2006 to 2010, (a) and
year by year (b). The in vitro EUCAST and
CLSI breakpoints for resistance are indicated
as dashed lines.
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sequence patterns in penicillin-binding protein-2 were identi-
ﬁed. Sequence pattern IV (four strains susceptible to
ceﬁxime with a MIC of 0.016 or 0.023 mg/L); sequence pat-
tern V (one strain with a MIC of 0.023 mg/L); sequence pat-
tern XIX (one strain with MIC of 0.023 mg/L) have been
previously reported [11,18,19]. An extra aspartate codon
(amino acid position 345) was observed in all of them. Iso-
lates with MIC ‡0.125 mg/L all shared the sequence pattern
XXXII (GenBank accession number AB511944). The latter,
already described [3,4], contained the three non-synonymous
nucleotide substitutions, resulting in amino acid alterations,
G545S, I312M and V316T related with reduced susceptibility
to cephalosporin. One strain (1050/09) showed a sequence
similar to the XIX penA pattern, from position 1 to 447, with
some modiﬁcations (GenBank accession number FR852576).
The sequence together with sequence XIX and that of a ref-
erence strain were reported (Appendix SI).
The sequence analysis showed relative homogeneous
genetic background. In particular, all the mtrR genes har-
boured the single deletion of A in the promoter region,
except for two harbouring the missense mutation A39T, as
previously described [10]. The strains with these mtrR pro-
moters displayed ceﬁxime MIC values of 0.016 and
0.023 mg/L, respectively. Only one ceﬁxime-susceptible iso-
TABLE 2. Susceptibility to ceﬁxime and ceftriaxone, and description of molecular analyses of a subsample of 50 Italian gono-
cocci
Code/year
of isolation
MIC of ceﬁxime
(mg/L)
MIC of ceftriaxone
(mg/L)
Sequence type
(por allele–tbpB allele) penA mtrR ponA porB1b
973/2009 0.38 0.064 1407 (908–110)
2157/2010 0.38 0.094 5107a (3096–4)
974/2008 0.25 0.064 1407 (908–110)
1037/2009 0.25 0.047 1407 (908–110)
1046/2009 0.25 0.094 1407 (908–110)
1076/2009 0.25 0.064 1407 (908–110)
2016/2009 0.25 0.032 1407 (908–110)
2017/2009 0.25 0.032 1407 (908–110)
2038/2010 0.25 0.094 1407 (908–110)
2097/2010 0.25 0.032 1407 (908–110)
950/2009 0.19 0.094 1407 (908–110)
982/2009 0.19 0.047 2212 (1388–110)
1021/2009 0.19 0.064 4359a (2672–110)
1035/2008 0.19 0.094 1407 (908–110)
1057/2009 0.19 0.064 1407 (908–110)
2021/2010 0.19 0.047 4973a (3013–110)
2039/2010 0.19 0.047 1407 (908–110)
2050/2010 0.19 0.032 1407 (908–110)
2090/2010 0.19 0.047 1407 (908–110)
2092/2010 0.19 0.047 1407 (908–110)
2098/2010 0.19 0.064 1407 (908–110)
2113/2010 0.19 0.047 2212 (1388–110) XXXII A delb L421P G101K, A102N
2134/2010 0.19 0.047 2212 (1388–110)
649/2007 0.125 0.032 2369 (1471–110)
980/2009 0.125 0.064 1407 (908–110)
989/2009 0.125 0.047 1407 (908–110)
990/2009 0.125 0.047 1407 (908–110)
992/2009 0.125 0.094 3499 (2115–110)
1011/2009 0.125 0.047 1407 (908–110)
1017/2009 0.125 0.008 1407 (908–110)
1018/2009 0.125 0.023 1407 (908–110)
1033/2008 0.125 0.064 4358a (962–110)
1036/2008 0.125 0.064 1407 (908–110)
1042/2008 0.125 0.064 1407 (908–110)
2032/2010 0.125 0.023 1407 (908–110)
2034/2010 0.125 0.032 1407 (908–110)
2047/2010 0.125 0.023 1407 (908–110)
2068/2010 0.125 0.032 1407 (908–110)
2084/2010 0.125 0.023 4974a (3014–110)
2111/2010 0.125 0.064 1407 (908–110)
2116/2010 0.125 0.016 4975a (3015–1042)
2150/2010 0.125 0.023 1407 (908–110)
2152/2010 0.125 0.064 4359 (2672–110)
1050/2009 0.032 0.032 141 (147–4) FR852576c A delb L421P G101K, A102D
978/2009 0.023 0.023 4517a (1907–955) V A delb L421P G101K, A102N
987/2009 0.023 0.016 4518a (242–955) IV A delb L421P G101K, A102D
1045/2009 0.016 0.023 225 (4–4) IV A delb L421P G101K, A102D
1027/2009 0.023 0.012 2142 (997–522) XIX A39T L421P G101K, A102N
1028/2009 0.016 0.012 4360a (1903–919) IV A39T L421P G101K, A102N
1082/2009 0.016 0.004 4421a (2301–21) IV Adelb; G45D wtd wtd
aNew sequence types.
bA del, presence of alanine deletion in the promoter region of mtrR.
cA new N. gonorrhoeae complete penA gene for Penicillin Binding Protein 2 deposited in the EMBL/GenBank nucleotide sequence database.
dwt, strains do not contain the ponA amino acid alteration L421P and the changes at amino acids 101 and 102 in the porB1b gene.
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late harboured the single deletion of A in the mtrR promoter
and also the G45D amino acid in the DNA-binding motif of
MtrR. The ponA1 allele with the L421P substitution was
detected in all the strains except for strain 1082/09. Also for
porB1b sequence, the allele possessed G101K and A102N
substitutions in the most isolates analysed (46 out of 50).
Strain 1082/09 had wild-type allele, and three other strains
(987/09, 1045/09 and 1050/09) possessed G101K and A102D
substitutions (Table 2).
A total of 17 sequence types were identiﬁed by NG-
MAST. Ten had not been previously described because of
the presence of new alleles (ﬁve because of a new por allele
and three because of new tbpB alleles), and two because of a
new combination (Table 2). ST1407, already described in
ceﬁxime-resistant strains worldwide [3,19], was the most
frequently found sequence type (31/50; 62%) among strains
with MIC ‡0.125 mg/L including the two strains with a MIC
of 0.38 mg/L. There was a signiﬁcant association between
decreased susceptibility/resistance to ceﬁxime and the
ST1407 (p <0.05). Moreover, for seven isolates the tbpB 110
was in combination with different por alleles generating dif-
ferent sequence types. The similarity among the por alleles is
shown in Fig. 2.
PFGE analysis showed a high similarity among isolates
belonging to the ST1407 dividing the isolates into two closely
related groups (Fig. 3).
Discussion
We provide a comprehensive analysis of susceptibility to ce-
ﬁxime and ceftriaxone in gonococcal isolates from Italy, com-
bined with their genetic characterization of putative
resistance determinants to cephalosporins and clonal compo-
sition.
Sustained circulation of isolates with a decreased suscepti-
bility to oral cephalosporins, such as ceﬁxime, has been
found in Italy and using the EUCAST breakpoint, this corre-
sponds to 12% resistance among the isolates examined. Sus-
ceptibility to ceﬁxime varied over time with fully susceptible
isolates displaying lower MIC values detected in the ﬁrst
years of the study period. Moreover, as strains with
MIC = 0.125 mg/L, a value close to the EUCAST breakpoint,
are currently found among the Italian gonococci, there is a
clear need for continuous surveillance.
Neisseria gonorrhoeae can easily acquire or select resistance
determinants with subsequent dissemination of resistant
strains. Following the emergence and spread of resistance to
sulfonamide in the 1940s, penicillin and tetracycline in the
1980s and lastly, ﬂuoroquinolones in the early 1990s, third-
generation cephalosporins have become the ﬁrst option of
treatment in most countries [6,20,21]. Neisseria gonorrhoeae
strains with reduced susceptibility to oral third-generation
por 962
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FIG. 2. Homology tree obtained with por alleles among strains with
MIC ‡0.125 mg/L associated with the 110 tbpB allele identifying the
ST1407 by Neisseria gonorrhoeae multi-antigen sequence typing.
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FIG. 3. Dendrogram of similarity obtained with Dice coefﬁcients
and arithmetic averages (UPGMA) clustering method using
BIONUMERICS software (version 3.5) showing the relatedness of pulsed
ﬁeld gel electrophoresis patterns for representative Neisseria gonor-
rhoeae strains fully susceptible or resistant to ceﬁxime. The proﬁles
are classiﬁed into two major clusters (A and B). Isolates that pro-
duced patterns that were <85% similar (see scale in the upper left
corner) were considered different. The isolate numbers, MICs and
sequence types are indicated and referred to in Table 2.
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cephalosporins have been described in Japan [18,21] Sweden
[22] Australia [19,23] and Greece [24].
For uncomplicated gonorrhoea infections, the CDC rec-
ommends 125 mg ceftriaxone intramuscularly [25] and the
International Union against Sexually Transmitted Infections
(IUSTI)/WHO guidelines give a dose of 250 mg ceftriaxone
intramuscularly [26]. Treatment failure occurs more fre-
quently with pharyngeal infection even when the infecting
organism remains fully susceptible to the antibiotic used
[27]. The recognition of resistance determinants to cephalo-
sporins, penA mosaic alleles or alteration in other target
genes, mtrR, ponA, porB1b, is crucial to monitoring the
emergence and spread of isolates with decreased cephalo-
sporin susceptibility in both national and international sur-
veillance systems. Alterations in additional genes such as
mutations in pilQ (previously known as penC) and mutations
in ponA encoding penicillin-binding protein-1 [28] have also
been suggested to contribute to decreased susceptibility or
resistance.
In the present study, we showed an association between
reduced susceptibility to ceﬁxime of N. gonorrhoeae isolates
and mutations in the penA gene. In particular, the penA
mosaic structure was found among strains with MIC of
0.125 mg/L or more, corresponding to penicillin-binding pro-
tein-2 amino acid sequence pattern XXXII. Moreover, a new
pattern, but resembling pattern XIX, was found in a sensitive
strain.
The increasing ceﬁxime MIC values among Italian isolates
is worrisome. The penA gene alterations served as a genetic
marker involved in this phenomenon whereas no association
between polymorphisms in the alleles for mtrR, penB1b and
ponA and increased ceﬁxime MICs was detected. Continued
molecular surveillance of genetic changes may be useful to
conﬁrm or predict clinically resistant isolates and so help to
improve gonorrhoea treatment, prevention and disease
spread.
In recent years sequence-based methods have been
favoured for molecular typing of resistant isolates as these
allow simple inter-laboratory comparison of isolates. The
most widely used current method of typing gonococci is the
NG-MAST, which indexes nucleotide sequence variation in
both por and tbpB and assigns isolates to sequence types
based on the alleles present at these two loci [15].
Moreover, gonococcal strains such as ST1407, and its
genetically related strains, possess different por sequences
and account for the majority of isolates with MIC
‡0.125 mg/L. The por gene, encoding the cell surface antigen,
is subject to selective pressures by the human immune
response and its mutation suggests that from a single
sequence type, gonococci rapidly diversify into multiple
sequence types. [15]. Despite the high genetic divergence
among gonococci, the limited spread of the internationally
recognized ceﬁxime-resistant strains, such as ST1407, was
also identiﬁed in Italy. The Italian ST1407 gonococci with ce-
ﬁxime MIC ‡0.125 mg/L were grouped into two clusters by
PFGE analysis, suggesting a high level of similarity among
strains.
The global spread of ceﬁxime resistance might be under-
estimated because different surveillance systems are used in
each country. Detecting cases of treatment failure is difﬁcult,
so it is essential to monitor the situation and consider it in
both a European and a global context, such as the sentinel
surveillance that was recently published for antimicrobial-
resistant gonorrhoea by ECDC (http://www.ecdc.europa.eu/
en/publications/Publications/1101_SUR_Gonococcal_suscepti-
bility_2009.pdf). Additionally, local surveillance enables in
depth analysis of phenotypic and genotypic resistance pat-
terns over time. In conclusion, the present results emphasize
an upward drift in MICs for ceﬁxime in Italy, underscoring
the need to monitor this situation closely over time. Inject-
able ceftriaxone is still a valuable drug for gonorrhoea treat-
ment in Itlay. Decreased susceptibility is related to penA
gene mosaicism and the majority of Italian isolates appeared
to be clonally related, belonging to ST1407.
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